🇺🇸 FDA

Company profile · Sponsor

enGene

enGene Therapeutics

ENGN · NYSE biotech SAINT-LAURENT, USA
Pipeline
2
Drugs
1
Patents
8

Quick answer

enGene (ENGN) is a biotech company. headquartered in SAINT-LAURENT, USA. listed on NYSE. NovaPharmaNews links 2 pipeline programs, 1 drug, and 8 patents to this profile..

Company facts

Ticker ENGN
Exchange NYSE
Company type biotech
Headquarters SAINT-LAURENT, USA
SEC CIK 0001980845

Pipeline (2)

Search pipeline →

  1. A Phase 1/2 Study of EG-70 as an Intravesical Administration to Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) and High-Risk NMIBC Patients who are BCG Naïve or Received Incomplete BCG Treatment

    enGene

    Non-muscle invasive bladder cancer (NMIBC)

    phase 2 other active

    1 trial

  2. EG-70 (phase 1)

    enGene

    Superficial Bladder Cancer

    phase 2 small molecule active

    1 trial

Drugs (1)

Search drugs →

  1. linvoseltamab-gcpt

    LYNOZYFIC

    INJECTION approved

Patents (8)

Search patents →

  1. US 12421273

    Ectonucleotidase inhibitors and methods of use thereof

    Expires Mon Sep 18 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12414968

    Compositions comprising bacterially derived minicells and methods of using the same

    Expires Mon Sep 11 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 12357687

    Compositions and vaccines for treating and/or preventing viral infections, and methods of using the same

    Expires Mon Jul 10 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 12337033

    Encapsulated glycolipid antigens for treatment of neoplastic diseases

    Expires Mon Jun 19 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 12076418

    Dually derivatized chitosan nanoparticles and methods of making and using the same for gene transfer in vivo

    Expires Mon Aug 29 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 11964021

    Bacterially derived, intact minicells for delivery of therapeutic agents to brain tumors

    Expires Mon Apr 18 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 11883433

    Chimeric antigen receptor comprising anti-mesothelin scFv, and use thereof

    Expires Mon Jan 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 11858957

    Ectonucleotidase inhibitors and methods of use thereof

    Expires Mon Dec 28 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is enGene?

enGene (ENGN) is a biotech company. headquartered in SAINT-LAURENT, USA. listed on NYSE. NovaPharmaNews links 2 pipeline programs, 1 drug, and 8 patents to this profile..

What pipeline programs does enGene sponsor?

We track 2 ClinicalTrials.gov-linked programs for enGene, including A Phase 1/2 Study of EG-70 as an Intravesical Administration to Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) and High-Risk NMIBC Patients who are BCG Naïve or Received Incomplete BCG Treatment and 1 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does enGene company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.